Polo-like kinase inhibitors

A compound of the formula

• wherein
• R1 is selected from the group consisting of hydrogen, halo, amino, alkylamino, C1-4 alkoxy, C1-4 alkyl, and SOxX1
• x is selected from the group consisting of 0, 1, and 2;
• Xi is selected from the group consisting of optionally substituted C1-4 alkyl, optionally substituted C3-8 cycloalkyl, and optionally substituted C4-12 aryl;
• R2 is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
• R3 is selected from the group consisting of amino, hydrogen, halo, nitro, cyano, optionally substituted C1-6 alkyl, C1-4 alkoxy, C1-9 amide, C1-5 oxycarbonyl, and N(X2)(X3),
• X2 is selected from the group consisting of hydrogen and C1-4 alkyl and X3 is selected from the group consisting of C1-4 alkyl, C1-7 alkylcarbonyl, and C1-6 sulfonyl;
• n is selected from the group consisting of 1 and 2;
• R4, each time taken, is independently selected from the group consisting of hydrogen, halo, hydroxy, optionally substituted C1-10 alkyl, optionally substituted C4-12 aryloxy, optionally substituted heteroC1-10 aryloxy, optionally substituted C3-8 cycloalkyl, optionally substituted C4-12 aryl, and optionally substituted heteroC1-10 aryl;
• R5, each time taken, is independently selected from the group consisting of hydrogen, halo, optionally substituted C1-10 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C4-12 aryl, and optionally substituted heteroC1-10 aryl;
• or
• R4 and R5 taken together with the carbon to which they are attached to form C═O;
• or
• R4 and R5 taken together with the carbon to which they are attached form an optionally substituted C3-8 cycloalkyl ring;
• or
• when n is 2, one of R4 or R5 on different carbons is taken together along with the carbons to which they are attached to form an optionally substituted C3-8 cycloalkyl ring;
• R6 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, C1-3 sulfonyl, and optionally substituted C3-8 cycloalkyl;
• R7 is hydrogen or a substituent convertible in vivo to hydrogen;
• R8 is selected from the group consisting of optionally substituted C4-12 arylene, optionally substituted heteroC1-10 arylene, optionally substituted C3-8 cycloalkylene, optionally substituted heteroC3-6 cycloalkylene, optionally substituted C7-12 bicycloalkylene, and optionally substituted heteroC3-12 bicycloalkylene;
• R9 is selected from the group consisting of —CONJ9-, —NJ9CO—, —NJ9-, —SO2NJ9-, —NJ9SO2—,
• J9 is selected from the group consisting of hydrogen and C1-4 alkyl;
• R10 is selected from the group consisting of optionally substituted C4-12 arylene, optionally substituted heteroC1-10 arylene, optionally substituted C3-8 cycloalkylene, optionally substituted heteroC3-6 cycloalkylene, optionally substituted C7-12 bicycloalkylene, and optionally substituted heteroC3-12 bicycloalkylene;
• R11 is selected from the group consisting of optionally substituted C1-4 alkylene, optionally substituted C1-4 azaalkylene, optionally substituted C3-8 cycloalkylene, and optionally substituted heteroC3-6 cycloalkylene;
• R12 is optionally substituted C3-8 cycloalkyl, when R11 is selected from the group consisting of optionally substituted C1-4 alkylene and optionally substituted C1-4 azaalkylene;
• R12 is optionally substituted C1-4 alkyl, when R11 is selected from the group consisting of optionally substituted C3-8 cycloalkylene and optionally substituted heteroC3-6 cycloalkylene;
• W is N or CR13;
• R13 is selected from the group consisting of hydrogen, halo, nitro, cyano, optionally substituted C1-6 alkyl, and optionally substituted C1-4 alkoxy;
• and pharmaceutically acceptable salts thereof.